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ABSTRACT
Objectives: We aimed to assess the association
between long-term use of inhaled corticosteroids (ICS)
and bone adverse effects in patients with asthma.
Design: Systematic review and meta-analysis of
fracture risk and changes in bone mineral density with
long-term ICS use in asthma.
Methods: We initially searched MEDLINE and
EMBASE in July 2013, and performed an updated
PubMed search in December 2014. We selected
randomised controlled trials (RCTs) and controlled
observational studies of any ICS (duration at least
12 months) compared to non-ICS use in patients with
asthma. We conducted meta-analysis of ORs for
fractures, and mean differences in bone mineral
density. Heterogeneity was assessed using the I2
statistic.
Results: We included 18 studies (7 RCTs and 11
observational studies) in the systematic review. Meta-
analysis of observational studies did not demonstrate
any significant association between ICS and fractures
in children (pooled OR 1.02, 95% CI 0.94 to 1.10, two
studies), or adults (pooled OR 1.09, 95% CI 0.45 to
2.62, four studies). Three RCTs and three observational
studies in children reported on bone mineral density at
the lumbar spine, and our meta-analysis did not show
significant reductions with ICS use. Three RCTs and
four observational studies in adults reported on ICS
use and bone mineral density at the lumbar spine and
femur, with no significant reductions found in the
meta-analysis compared to control.
Conclusions: ICS use for ≥12 months in adults or
children with asthma was not significantly associated
with harmful effects on fractures or bone mineral
density.
INTRODUCTION
Asthma is a chronic inﬂammatory condition
that affects both adults and children. There
is a substantial body of evidence that suggest
inhaled corticosteroids (ICS) are effective
at controlling symptoms, improving lung
function and reducing acute exacerbations.1
They are therefore considered the gold
standard ﬁrst-line preventative therapy and
are widely recommended in national and
international guidelines.2 3
However, long-term ICS use may be asso-
ciated with adverse effects such as cataract,
osteoporosis, fractures and reduction in
growth velocity in children.4 Concerns sur-
rounding these potential harms may have a
negative effect on ICS adherence, thus expos-
ing patients to poorer asthma control and a
potentially higher risk of needing oral corti-
costeroids for acute exacerbations.4 Certain
age groups, such as children or postmenopau-
sal women may be particularly susceptible to
adverse effects on bone metabolism and for-
mation, and this therefore remains an area of
concern for these patients.
The existing meta-analyses of ICS and bone
adverse effects have usually included data
from participants with chronic obstructive pul-
monary disease (COPD)5–7 and to date, there
has been less focus on the effects in asthma
alone. Patients with asthma may not share the
same susceptibilities to osteoporosis as the
patient with COPD because of differences in
risk factors such as cigarette consumption,
multimorbidity and nutritional problems that
are prevalent in patients with COPD.8 9 It
Strengths and limitations of this study
▪ Comprehensive search of two databases with
independent study selection and data extraction.
▪ Included both observational and randomised
studies in adults and/or children with asthma.
▪ Heterogenous nature of studies and the outcome
measures which were available for analysis.
▪ Inability to properly assess differences between
drugs, type of inhaler device or dose-
responsiveness.
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therefore remains unclear whether patients with asthma
have a greater or lesser risk of bone adverse effects than
those with COPD and a further review is necessary to
clarify these risks for patients with asthma alone.
Hence we aimed to analyse the effects of long-term
(≥12 months) ICS use in patients with asthma alone,
concentrating on fracture and bone mineral density
(BMD) outcomes.
METHODS
Study selection criteria
We aimed to focus on long-term, important but infre-
quent adverse effects on bone and as such, eligible
studies had to have >20 users of each ICS formulation,
with follow-up of at least 12 months in duration.
Our inclusion criteria for RCTs were (1) parallel-group
RCT; (2) participants with asthma of any severity; (3) ICS
as the intervention versus a control treatment, where the
comparison groups consisted of ICS versus other asthma
therapy (or placebo), or ICS in combination with long-
acting β-agonist (LABA) versus a LABA alone; and (4)
stated aim to evaluate fractures or BMD.
We also evaluated controlled observational studies (case
control, prospective cohort or retrospective cohort)
reporting on risk of fractures or change in BMD with any
ICS exposure compared to those without ICS exposure.
Exclusion criteria
We excluded studies that recruited mixed groups of par-
ticipants (asthma/COPD) if the outcomes were not sep-
arately reported according to speciﬁc disease condition.
We excluded crossover trials and studies that considered
only oral corticosteroid use without reporting the effects
of inhaled corticosteroids.
Search strategy
We initially searched MEDLINE and EMBASE in June
2013 using a broad strategy for a wide range of adverse
effects potentially associated with ICS use, and we subse-
quently updated this through a more focused PubMed
search in December 2014 (see eAppendix 1 for search
terms and restrictions). We also manually looked
through the bibliographies of included studies as well as
existing systematic reviews for any other articles that may
be potentially suitable.
Study selection
Two reviewers (MT and PB) independently, and in dupli-
cate scanned all titles and abstracts and excluded articles
that clearly were not RCTs or observational studies of
ICS in patients with asthma. We proceeded to assess
full-text versions of potentially relevant articles and con-
ducted more detailed checks against our eligibility cri-
teria, focusing on bone and fracture adverse effects. A
third researcher (YKL or AMW) evaluated the decision
on inclusion or exclusion in discussion with the two
reviewers.
Study characteristics and data extraction
We used preformatted tables to record study design and
participant characteristics, deﬁnition of asthma, pharma-
cological agent (dose, device and frequency), and dur-
ation of follow-up. Two reviewers independently
extracted data (MT and PB) on relevant outcomes,
where we prespeciﬁed fracture risk of primary interest,
and BMD at the lumbar spine or the femur as secondary
end points. Any discrepancies were resolved through the
involvement of a third reviewer (DG or YKL or AMW)
after rechecking the source papers.
Risk of bias assessment
Two reviewers independently assessed the reporting of
blinding of participants and personnel, randomisation
sequence, allocation concealment, withdrawals and the
loss to follow-up in RCTs. In order to assess validity of
the associations between adverse effects and ICS use, we
extracted information on participant selection, ascertain-
ment of exposure and outcomes, and methods of
addressing confounding in observational studies.10
We aimed to use a funnel plot and asymmetry testing
to assess publication bias provided that there were more
than 10 studies in the meta-analysis, and the absence of
signiﬁcant heterogeneity.11
Statistical analysis
We pooled trial data using Review Manager (RevMan)
V.5.3.2 (Nordic Cochrane Center, Copenhagen,
Denmark). We used the inverse variance method to
pool ORs for fracture events, and mean differences for
BMD (g/cm2). In accordance with the recommenda-
tions of the Cochrane Handbook, we derived any SDs
from 95% CIs or p values.12 We assessed statistical het-
erogeneity using the I2 statistic with I2>50% indicating a
substantial level of heterogeneity.
If a trial had more than one group of non-ICS users as
controls, we analysed data for ICS versus placebo (if
available) in preference to data from active comparators
such as ICS versus nedocromil, montelukast or disodium
cromoglycate. If combination formulations were evalu-
ated in the trial, we chose unconfounded comparisons
based on ICS used together with the other drug versus
other drug alone.
If a trial had several arms involving different ICS
doses, we combined all the ICS arms together as recom-
mended by the Cochrane Handbook.13
We did not have a pre-registered protocol.
RESULTS
We screened 1887 potentially relevant articles, and
ﬁnally included 18 studies in our systematic review (com-
prising 7 RCTs,14–20and 11 observational studies).21–31
The process of study selection is shown in ﬁgure 1.
Table 1A, B show the characteristics of the included
RCTs, and the observational studies, respectively.
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Tables 2 and 3 report on study validity and outcomes in
adult and children, respectively.
Four of the RCTs focused solely on children,14 15 19 20
while the remaining three were in adults.16–18 Treatment
duration was up to 4 years in one study,15 while the
remaining six trials had ICS therapy for between 52 and
104 weeks. Intervention arms of the trials included ﬂuti-
casone (5 trials), budesonide (3 trials) and mometasone
(one trial). Fluticasone and mometasone were the ICS
used in the intervention arms of one trial, and in this
trial, we evaluated the results of all ICS users combined
against montelukast.18
Five of the observational studies focused solely on chil-
dren,21–23 25 29 while the remainder looked at adults or a
mixture of age groups. The observational studies looked
at wider range of ICS than the RCTs, with the inclusion
of beclometasone, ﬂunisolide and triamcinolone users.
Study validity
Validity assessment of the included studies is reported in
tables 2 and 3.
Randomised controlled trials (n=7)
Overall, four of the RCTs reported an appropriate
method of sequence generation, while ﬁve provided
details on how concealment of allocation was achieved.
With regards to blinding, ﬁve trials reported the use of
double-blinding. Ascertainment of BMD was consistently
performed through dual-energy X-ray absorptiometry
(DEXA) scans, but the trials did not state how and when
fracture diagnoses were conﬁrmed. One major limita-
tion that affected all the trials stemmed from disconti-
nuations and substantial losses to follow-up for
measurement of BMD outcomes at ﬁnal time-points.
Observational studies (n=11)
We felt that only four studies took account of a good
range of variables when tackling baseline confound-
ing.26 27 29 30 Assessment of compliance or adherence to
ICS use was reported in four studies.21 22 30 31 Fracture
events were typically recorded through administrative
codes while one study relied on patient self-report.
Ascertainment of BMD was through DEXA scans.
Overall, we felt that most of the studies were at moderate
to high risk of bias due to the above limitations, with
four studies possibly of slightly better methodological
quality because of adequate outcome ascertainment and
adjustment for confounders.26 27 29 30
Fractures with ICS
We identiﬁed one large long-term RCT in children that
reported adjusted fracture rate of 5.7 per 100 patient
years with budesonide as compared to 5.1 per 100
patient years with placebo (p=0.53).32 Similarly, there
was no signiﬁcant increase in likelihood of fracture in a
meta-analysis of two observational studies in children,
(OR 1.02, 95% CI 0.94 to 1.10, I2=0%)27 29 as shown in
ﬁgure 2. The point estimates of fracture risk was not
Figure 1 Flow diagram of study
selection. BMD, bone mineral
density; RCT, randomised
controlled trial.
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Table 1 Characteristics of included trials and observational studies
(A) Randomised controlled trials
Source Location
Treatment
duration Asthma criteria Drug and inhaler device
Male
%
Mean
age
(years)
Mean %
predicted
FEV1
Prior ICS
use (%)
CAMP/Kelly
et al15 32
Multicentre US >208 weeks Mild-to-moderate asthma defined by
symptoms or by use of inhaled
bronchodilator ≥ twice weekly or daily
medication for asthma. Airway
methacholine challenge test
BUD 200 µg bd (n=311) 58.2 9.0 93.6 40.5
Nedocromil 8 mg daily
(n=312)
66.0 8.8 93.4 36.5
Placebo (n=412) 56.0 9.0 94.2 35.9
Ferguson
et al 200714
Multicentre—35
centres in 11
countries
52 weeks Age 6–9 years persistent asthma
≥6 months; FEV1 ≥ 60% predicted;
↑PEFR of ≥15% after salbutamol.
Exclusions: oral corticosteroids on >2
occasions or >12 days or >210 mg
prednisolone past 6 months; known growth
disorder or glaucoma/cataracts
FP 100 μg bd (n=114)
Diskus (dry powder inhaler)
68 7.2 90.2 25% oral
steroids past
6 months
BUD 200 μg bd (n=119)
Turbuhaler
70 7.4 92.3 21% oral
steroids past
6months
Kemp
et al16
Multicentre US 104 weeks 6-month history of mild asthma (FEV1
82–85% predicted) able to be managed
without steroids for 2 years
FP 88 µg bd (n=55)
Metered dose inhaler
60 31.6 83 0
FP 440 µg bd (n=51)
Metered dose inhaler
59 29.0 82 0
Placebo (n=54) 59 28.4 85 0
Li et al17 Multicentre US 104 weeks At least 6-month history with diagnosis
using American Thoracic Society
definition. FEV1 of ≥60% predicted, and
limited previous corticosteroid therapy
FP 500 μg bd (n=32)
Diskhaler
91 28.0 91 Not reported
Placebo bd (n=32)
Diskhaler
81 31.1 91 Not reported
Maspero
et al18
50 centres
worldwide
52 weeks Adults with >3 months history of asthma,
and not using ICS past 3 months. FEV1
between 60 and 90% predicted. Must
have DEXA scan, and no evidence of low
vitamin D
Mometasone 400 µg daily
(n=137)
34 30 76.5 7
Mometasone 200 µg daily
(n=140)
35 30 74.7 7
FP 250 µg bd (n=147) 39 28 75.3 6
Montelukast 10 mg (n=142) 38 28 76.9 10
Roux et al19 52 respiratory
specialist clinics
in France
104 weeks Exacerbations ≥1×/week but <1× daily; or
chronic symptoms requiring daily
treatment. Fulfilling: (1) FEV1 or PEFR
≥80% predicted; (2) reversibility ≥15%; (3)
daily variability PEFR 20%–30% ≥2 days,
or salbutamol use >3 times previous
week, or nocturnal symptoms ≥2× during
run-in
FP 100 μg bd (n=87)
Diskus/Accuhaler dry
powder inhaler
64 9.1 88.9 Not reported
Nedocromil 4 mg bd (n=87)
MDI
66 9.4 88.5 Not reported
Turpeinen
et al20
Helsinki
University
Hospital,
Finland
72 weeks ‘Newly detected mild asthma’
Excluded if history of inhaled, nasal or oral
corticosteroid use in the previous
2 months before enrolment
Continuous BUD (n=50)
Turbuhaler
BUD 400 μg bd for
1 month, then 200 μg bd for
60 6.9 Not reported Not reported
Continued
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Table 1 Continued
(A) Randomised controlled trials
Source Location
Treatment
duration Asthma criteria Drug and inhaler device
Male
%
Mean
age
(years)
Mean %
predicted
FEV1
Prior ICS
use (%)
2nd–6th months, then
100 μg bd for final
12 months.
BUD/placebo (n=44)
Turbuhaler
BUD 400 μg bd for 1st
month, then 200 μg bd for
2nd to 6th months, then
placebo for final 12 months
66 6.7 Not reported Not reported
Sodium cromoglicate—
10 mg tds for 18 months
(unblinded) (n=42)
MDI
50 7.0 Not reported Not reported
Bd, two times a day; BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; ICS, inhaled corticosteroids; MDI, metered
dose inhaler; PEFR, peak expiratory flow rate.
(B) Observational studies
Study Design
Adverse
effects
measured
Data source and number of
patients
Selection of patients: asthma definition
and patient characteristics (or selection of
cases and controls) Type of ICS
Agertoft and
Pedersen21
Cross-sectional study BMD Outpatient paediatric clinic, Kolding
Hospital, Denmark
157 cases, 111 controls
Selection of cases: Children with persistent
asthma and no other chronic disease, on ICS
continuously for ≥3 years.
Mean age: 10.3 years, male 69%, %FEV1
predicted: 97
Selection of controls: asthmatic children, who
have never taken inhaled/systemic
corticosteroids for >2 weeks per year.
Mean age: 9.9 years, male 55%, %FEV1
predicted: 81
BUD
Allen et al22 Prospective BMD Department of Paediatrics, Royal
North Shore Hospital, Sydney,
Australia
48 cases, 9 controls
Selection of cases: prepubertal asthmatic
children requiring >3 courses oral
corticosteroids within study period
Mean age: 7.8 years, male 63%
Selection of controls: children not using
corticosteroids.
Mean age: 8.4 years, male 78%
BDP, BUD
Continued
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Continued
(B) Observational studies
Study Design
Adverse
effects
measured
Data source and number of
patients
Selection of patients: asthma definition
and patient characteristics (or selection of
cases and controls) Type of ICS
Bahceciler
et al23
Cross-sectional study BMD Outpatient Allergy Clinic of Marmara
University Hospital, Istanbul, Turkey
52 cases, 22 controls
Asthma definition: mild intermittent plus
persistent mild to moderate asthma
Selection of cases: Children treated for
≥6 months.
Mean age: 6.4 years, male 42%
Characteristics of high-dose ICS group:
Mean age: 3 years
Mean duration of disease: 50.4 months
Characteristics of low dose ICS group:
Mean age: 5.8 years
Mean duration of disease: 38.3 months
Selection of controls: Age-matched asthmatic
children who have never received ICS
Mean age: 6.8 years, male 45%
BUD
El et al24 Observational BMD Outpatients, Dokuz Eylul University,
Balcova, Izmir, Turkey
45 cases, 46 controls
Asthma severity defined according to Global
Initiative for Asthma guideline
Selection of cases: patients with mild or
moderate asthma and regular ICS use. Mean
age: 44.04 years, male 0%, %FEV1: 89.71
Controls : Mean age: 44.43 years, male 0%
Not specified
Harris et al25 Cross-sectional study BMD Outpatient clinics of Sydney
Children’s Hospital, Randwick, New
South Wales and Monash Medical
Centre, Clayton, Victoria, Australia.
76 subjects
Selection of subjects:
Prepubertal asthmatic children stratified into
groups according to corticosteroid treatment
received in the past 6 months
1) no inhaled corticosteroid, mean age:
8.2 years, male 70%
2) moderate dose inhaled corticosteroid (400–
800 μg/day), mean age: 7.4 years, male 56%
3) high-dose inhaled corticosteroid (>800 µg/
day), mean age: 8.9 years, male 75%,
BDP, BUD, FP
Johannes
et al26
Nested case-control study Risk of
non-vertebral
fracture
Ingenix Epidemiology—Research
database of United Healthcare
members, 17 states in the USA.
1722 cases, 17 220 controls
Adults ≥40 years age, in health plan for ≥12
continuous months Jan 1997 to Jun 2001,
with ICD-9 code for asthma, or COPD
Selection of cases: Non-vertebral fractures by
ICD-9 codes, with claim for treatment
(including inpatient hip fractures)
Mean age 52.9 years, male 29.4%
BDP, BUD, FP
flunisolone,
triamcinolone
Continued
Table 1 Continued
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Continued
(B) Observational studies
Study Design
Adverse
effects
measured
Data source and number of
patients
Selection of patients: asthma definition
and patient characteristics (or selection of
cases and controls) Type of ICS
Selection of controls:
Sampled from person-time of respiratory
cohort by two-tiered random sampling with
replacement
Mean age 52.2 years, male 41.1%
Schlienger
et al27
Retrospective
Population-based nested
case-control analysis
Fracture risk UK General Practice Research
Database
3744 cases, 21 757 controls
Aged 5–79 years with ICD code for asthma or
COPD with ≥1 prescription for ICS and/or
OCS; or with no exposure to corticosteroids
From there 65 779 individuals aged 5–
17 years identified to form base population for
study
Selection of cases: Patients with 1st-time
diagnosis ICD-8 bone fracture; male 65.6%
Selection of controls: Up to 6 control subjects
selected per case, matched on age, gender,
general practice attended, calendar time and
years of history in GPRD; male 64.9%
76.2% BDP
21.7% BUD
2.1% FP
Sosa et al28 Cross-sectional study BMD; Fracture
risk
Canary Islands, Spain
105 cases; 133 controls
Selection of cases: Women suffering from
stable bronchial asthma, treated with ICS
≥1 year, and who did not receive oral or
parenteral steroids. Mean age: 53.0 years,
number of menopausal subjects n (%): 65
(61.9)
Selection of controls: weight-matched women,
no asthma and no steroids. Controls were
usually friends or neighbours of the patients.
Mean age: 49.7 years, number of menopausal
subjects n (%): 74 (57.8)
ICS formulations
not specified
Van Staa
et al29
Population-based cohort
study/nested case-control
analysis
Fracture risk UK General Practice Research
Database (GPRD)
Cohort: ICS users: 97 387
Bronchodilators only: 70 984
Controls: 345 758
Fracture cases: 23 984; Controls:
23 984
Children aged 4–17 years old, on ICS. 3 study
groups: selection of cases: non-vertebral
fracture. Male 61%, 8856 (36.9%) aged 4–
9 years, 8496 (35.4%) aged 10–13 years,
6632 (27.7%) aged 14–17 years
Selection of controls: for each fracture case,
one control patient randomly selected,
matched by age, sex, GP practice and
calendar time. Male 61%, 8861 (36.9%) aged
BDP, BUD, FP
Continued
Table 1 Continued
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Continued
(B) Observational studies
Study Design
Adverse
effects
measured
Data source and number of
patients
Selection of patients: asthma definition
and patient characteristics (or selection of
cases and controls) Type of ICS
4–9 years, 8497 (35.4%) aged 10–13 years,
6626 (27.6%) aged 14–17 years
Wisniewski
et al30
Cross-sectional study BMD Asthma register and local general
practices in Nottingham, UK
47 cases; 34 controls
Selection of cases: aged 20–40 years with
documented history of asthma:
Group 1: asthmatics using inhaled β2-agonist
only. Males 56%, mean age: men 30.3 years;
women 25.6 years, mean FEV1 (litres): men
3.87; women 3.13
Group 2: ICS use ≥5 years with no systemic
steroids in the past 6 months. Males 40%,
mean age: men 32.3 years; women 32 years,
mean FEV1 (litres): men 3.40; women 2.83
BDP, BUD
Yanik et al31 Observational BMD Pulmonology outpatient clinic at Fatih
University Faculty of Medicine,
Ankara, Turkey
46 cases, 60 controls
Selection of cases: Regular ICS use
≥12 months) as defined by The Global
Initiative for Asthma (GINA) criteria
Mean age: 62.5 years, male 0%, %FEV1
predicted: 83.1, All cases were
postmenopausal
Selection of controls: healthy postmenopausal
females. Mean age: 63 years
BDP, BUD, FP
BDP, beclomethasone dipropionate; BUD, budesonide; COPD, chronic obstructive pulmonary diseases; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; GP, general
practitioner; ICD, International Classification of Diseases; ICS, inhaled corticosteroids.
Table 1 Continued
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Table 2 Study validity and outcomes (bone mineral density and fractures) in children
(A) RCTs of inhaled corticosteroids—children
Source
Sequence
generation
Allocation
concealment
Blinding of
participants and
personnel AE monitoring Adverse events
Discontinued,
number (%)
Loss to
follow-up,
number (%)
CAMP/Kelly
et al15 32
Permuted blocks,
stratified
Adequate Adequate Height recorded at every visit;
BMD once every year
Fracture rate (adjusted for
age, ethnic group, sex,
clinic, base line duration,
skin-test reactivity and
asthma severity):
BUD: 5.7 per 100
person-years
Placebo: 5.1 per 100
person-years
p=0.59
Mean difference in BMD
(ICS vs placebo):
Females: −0.001 (derived
SE 0.0016)
Male:−0.003 (derived SE
0.0014)
11% 5%
Ferguson
et al 200714
Not reported Remote
computerised
allocation
Adequate Lumbar-spine BMD assessed at
beginning and end of treatment
with DEXA scan
Mean difference in lumbar
spine BMD for FP vs
BUD: 0.0075 (95% CI
−0.033 to 0.048)
90% patients
received
>40 weeks
26% did not
reach
51 weeks
Roux et al19 Central Block
randomisation with
gender
stratification
. Largely open.
Analysis of
DEXA scans
blinded
Lumber spine and femoral neck
BMD (DEXA) during run-in and
6, 12 and 24 months. Adjusted
for age, height, weight, baseline
BMD, gender and measuring
device
Mean difference in lumbar
spine BMD for FP vs
control: 0.012 (SE
0.0073); values calculated
from % change in
manuscript
23% 4%
Turpeinen
et al20
Block Unclear Blinded for
budesonide and
placebo arms
BMD of L1–4 measured by
radiologist using DEXA at
baseline and at 18 months
Mean change in lumbar
spine BMD:
Budesonide for
12 months 0.023 (SD
0.022)
Placebo for 12 months
0.029 (SD 0.022)
DSCG: 0.034 (SD 0.022)
20% 3%
BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; DSCG, disodium cromoglicate; FP, fluticasone propionate.
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(B) Observational studies of bone mineral density and fractures—children
Study Ascertainment of BMD
Ascertainment of
exposure Definition of ICS use Adjustments ICS exposure BMD (g/cm)
Agertoft and
Pedersen21
DEXA scan at one visit, performed by
same investigator blinded to treatment
group
Compliance
checked: Good
Duration:
Mean 1603 days
Asthmatic children with
ICS use continuously
for ≥3 years
Type of inhaler: MDI;
Turbuhaler
Type of steroid: BUD
Log of accumulated
dose of BUD; gender;
age
Mean ICS BUD
dose 504 μg
(daily)
Mean BMD:
BUD group: 0.92
Control group: 0.92
Allen et al22 DEXA scan at baseline and again at 9–
20 months later. Value for 12-month
time point calculated with all outcomes
Compliance
checked: Adequate
Duration of
follow-up: 9–
20 months
Type of inhaler:
Spacer, Turbohaler
Type of steroid: BDP,
BUD
Age; height; weight;
dose of inhaled
corticosteroid
Mean ICS dose
0.67±0.48 mg/
m2/day
Change in mean
vertebral BMD (SD)
over 12 months:
ICS group (n=47):
0.03±0.03
Control group
(n=9): 0.06±0.04
p:<0.025
Bahceciler
et al23
Anteroposterior (AP) spine (L2–4) by
DEXA scan
Compliance: not
reported
Follow-up: 13.0
±9.8 months
Use of BUD as MDI
≥6 months
None ICS Mean daily
dose (SD): 419
±154 μg
Mean lumbar spine
BMD:
ICS group: 0.593
(SD 0.122)
Control Mean lumbar spine
BMD: 0.579 (SD
0.156)
Harris et al25 Lumbar spine by DEXA Compliance
checked: not
reported
Duration of
follow-up: 3.5
±2.4 years
Stratified by treatment
in past 6 months
Type of inhaler: Spacer
device
Type of steroid: BDP,
BUD, FP
Weight 0 μg/day Mean lumbar spine
BMD (SD) 0.68
(0.07)
400–800 μg/day Mean lumbar spine
BMD (SD)
0.70 (0.08)
>800 μg/day Mean lumbar spine
BMD (SD)
0.67 (0.08)
Table 2 Continued
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Studies reporting on fracture risk
Fracture
outcomes
Schlienger
et al27
Identified by ICD-8
codes 800.x −829.x,
from computerised
records
Cases=1st-time
diagnosis of bone
fracture
Controls—no fracture
Compliance checked: not
reported
Duration:
Median number of
prescriptions: 26,
corresponds to >7 years
of continuous exposure
ICS use in UK
General
Practice
Research
Database
Type of inhaler:
not reported
Type of steroid:
BDP, BUD, FP
Matched for age, gender, general practice,
calendar time, years in GPRD Adjusted for
comorbidities: chronic renal failure,
hyperthyroidism, hyperparathyroidism,
inflammatory bowel disease, malnutrition,
malabsorption
Medications: asthma drugs, psychotropic
drugs, antihypertensives, calcium, fluoride,
vitamin D
1–9
prescriptions
Cases: n=332
Controls:
n=2017
Adjusted OR: 0.97
(0.85 to 1.11)
10–19
prescriptions
Cases: n=124
Controls: n=682
Adjusted OR: 1.08
(0.87 to 1.33)
≥20
prescriptions
Cases: n=88
Controls: n=422
Adjusted OR: 1.15
(0.89 to 1.48)
All ICS users
combined
Adjusted OR: 1.01
(0.90 to 1.13)
Van Staa
et al29
Ascertained from
diagnoses within
computer records
Compliance not reported
Start of follow-up:1987
onwards or from age
4 years
End: December 1997 or
age 18 years
Current users of
ICS
Type of inhaler:
not reported
Type of inhaled
steroid: BDP,
BUD, FP
History of seizures; use of non-steroidal
anti-inflammatory drugs or bronchodilators;
hospitalisation for asthma past 2 years;
number of prescriptions in past year. Age;
sex
200 μg Adjusted OR: 0.96
(0.83 to 1.12)
201–400 μg Adjusted OR: 1.07
(0.93 to 1.24)
>400 μg Adjusted OR: 1.17
(0.93 to 1.45)
All ICS users Adjusted OR: 1.03
(0.93 to 1.15)
BDP, beclometasone diproprionate; BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; FP, fluticasone propionate; ICD, International Classification of Disease; ICS, inhaled
corticosteroids; MDI, metered dose inhaler.
Table 2 Continued
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Table 3 Study validity and outcomes (bone mineral density and fractures) in adults
(a) RCTs of inhaled corticosteroids—adults
Source
Sequence
generation
Allocation
concealment
Blinding of
participants
and personnel AE monitoring Drug (n)
Mean change
in BMD g/cm2
Dis-continued,
number (%)
Loss to
follow-up,
number (%)
Kemp
et al16
Random code with
blinded labels
Adequate Adequate DEXA scan every
6 months at lumbar spine
(L1-L4). analysed by
central osteoporosis
research facility for quality
assurance
Adjusted for baseline
value, investigator, sex,
age
FP 88 µg bd At week 104
1) Lumbar
spine: 0.008,
SE 0.006
2) Proximal
femur: −0.009,
SE 0.009
17 (31) 6 (11)
FP 440 µg bd At week 104
1) lumbar
spine: -0.003,
SE 0.008
2) Proximal
femur: −-0.020,
SE 0.009
18 (35) 7 (14)
Placebo bd At week 104
1) Lumbar
spine: 0.001,
SE 0.005
2) Proximal
femur: −0.007,
SE 0.007
10 (19) 4 (7)
Li et al17 Unclear Unclear Adequate DEXA at L1-L4 of lumbar
spine. Measured at
screening and 6-month
intervals
FP At week 104,
lumbar spine:
−0.006, SE
0.008
9 (28) 2 (6)
Placebo At week 104,
lumbar spine:
−0.007, SE
0.010
8 (25) 7 (22)
Maspero
et al18
Centrally
administered
through interactive
voice response
system
Adequate Adequate DEXA at L1-L4 of lumbar
spine. Follow-up at 26 and
52 weeks
Mometasone
400 µg
1) Lumbar
spine: 0.0092)
Femur: 0.004
34 (25) 5 (3)
Mometasone
200 µg daily
1) Lumbar
spine: 0.0082)
Proximal femur:
0.004
35 (25) 7 (4)
FP 250 µg bd 1) Lumbar
spine: 0.0122)
Femur: −-0.005
38 (26) 4 (3)
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Table 3 Continued
(a) RCTs of inhaled corticosteroids—adults
Source
Sequence
generation
Allocation
concealment
Blinding of
participants
and personnel AE monitoring Drug (n)
Mean change
in BMD g/cm2
Dis-continued,
number (%)
Loss to
follow-up,
number (%)
Combined
estimate for all
ICS users
1) Lumbar
spine: 0.0092)
Femur: 0.0008
107 (25) 16 (4)
Montelukast
10 mg daily
1) Lumbar
spine: 0.0132)
Femur: −0.002
31 (22) 3 (3)
AE, adverse event; bd, two times a day; DEXA, dual-energy X-ray absorptiometry; FP, fluticasone propionate; ICS, inhaled corticosteroids; RCT, randomised controlled trial.
Observational studies of bone mineral density and fractures—adults
Study
Ascertainment of BMD/
fracture
Ascertainment of
ICS exposure Definition of ICS use Adjustments
ICS
exposure
Results of BMD (g/
cm2) and fractures
El et al24 DEXA lumbar spine (L1–4) and
femoral neck
Compliance checked:
poor
Duration:
mean duration (SD)
(years): 2.79±1.77
Regular ICS
>6 months
Type of inhaler: not
reported
Type of ICS: not
reported
Age Cases
Mean daily
ICS dose
326.43 µg
Mean lumbar: 0.925,
SD 0.211
Mean femoral neck:
0.746, SD 0.127
Controls (no
exposure)
Mean lumbar: BMD:
0.927, SD 0.229
Mean femoral neck:
0.792, SD 0.097
Johannes
et al26
Non-vertebral identified by
ICD-9 codes and insurance
claim for fracture treatment
within 2 weeks
Compliance checked:
not reported
Duration: 1 Year ICS
exposure
ICS use from
pharmacy claims in
the 365 days before
index date.
Type of inhaler: not
reported
Type of steroid: BDP,
BUD, FP, flunisolone,
triamcinolone
Demographics—age, sex, region,
time and season
Comorbidities—wide range of
cardiovascular, endocrine,
metabolic and musculoskeletal
conditions
Medications—oral corticosteroids,
bisphosphonates, statins,
anticonvulsants, oestrogen,
raloxifene, calcitonin
Healthcare utilisation for
underlying respiratory disease
1–167 μg OR 1.00
95% CI 0.84 to 1.18
168–504 μg OR: 1.02
95% CI 0.83 to 1.26
505–840 μg OR: 1.14
95% CI 0.80 to 1.62
>840 μg 0.99
95% CI 0.66 to 1.50
Sosa et al28 DEXA
lumbar spine (L2-L4) and
proximal femur
Compliance: not
reported
Duration of follow up:
ICS for >1 year
Type of inhaler: not
reported
Age Cases (dose
not
reported)
Lumbar spine:
0.960; 95% CI 0.925
to 0.995
Femoral neck:0.776;
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Continued
Observational studies of bone mineral density and fractures—adults
Study
Ascertainment of BMD/
fracture
Ascertainment of
ICS exposure Definition of ICS use Adjustments
ICS
exposure
Results of BMD (g/
cm2) and fractures
Median treatment
with ICS: 10 years
Type of ICS: not
reported
95% CI 0.750 to
0.802
Fractures: 22/105
(21.0%)
Controls Lumbar spine:
0.991; 95% CI 0.960
to 1.022
Femoral neck:
0.780; 95% CI 0.758
to 0.803
Fractures: 9/133
(7.0%)
Wisniewski
et al30
Posterior-anterior spine (L2–4),
lateral spine (body of L3)
measured by DEXA once. All
scans by same radiographer
(blinded)
Compliance checked:
Adequate
Duration:
Median duration of
use of ICS (years)
Men: 9.00
Women: 6.29
ICS for > 5 years
Type of inhaler:
Metered dose inhaler
—36 patients; dry
powder inhaler—11
patients
Type of ICS: BDP,
BUD
age; weight; smoking; alcohol;
activity grade; asthma severity;
age at menarche; lifetime total
dose of oestrogen and
progesterone; prednisolone use
Cases Lumbar spine±SD
Men : 1.28±0.13;
Women: 1.04±0.14
Femoral neck±SD:
Men : 1.17±0.18;
Women: 1.09±0.14
Vertebral fractures
overall: 2/47
Controls (No
exposure)
Lumbar spine±SD
Men:1.21±0.17;
Women: 1.25±0.12
Femoral neck±SD:
Men : 1.04±0.14;
Women: 1.10±0.14
Vertebral fractures
overall: 6/34
Yanik et al31 DEXA lumbar spine and hip
(femoral neck and trochanter).
Patient-reported history of
fractures
Compliance checked:
Adequate
Duration of
Follow-up: 4.3
±2.6 years
Regular ICS
>12 months
Type of inhaler: Not
reported
Type of ICS:
BDP, BUD, FP
None Cases
(total)
Mean daily
ICS dose
(μg) (SD):
324.9±121.8
Lumbar spine± SD
0.95±0.29
Femoral neck± SD
0.83±0.12
Atraumatic vertebral
fractures: 4 (8.6%)
Controls Lumbar spine±SD
0.88±0.14
Femoral neck±SD
0.74±0.23
Atraumatic vertebral
fracture: 6 (10%)
BDP, beclometasone diproprionate; BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; FP, fluticasone propionate; ICD, International Classification of Disease; ICS, inhaled
corticosteroids.
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signiﬁcantly elevated at higher dose levels, with one
study demonstrating an OR of 1.15 (0.89 to 1.48) for
children with ≥20 prescriptions,27 and the other study
reporting an OR of 1.17 (0.93 to 1.45) for children
using a daily dose of >400 μg beclomethasone dipropio-
nate equivalents.29
No consistent association between ICS use and frac-
ture risk in adults was seen in the pooled estimate from
four observational studies (overall OR 1.09, 95% CI 0.45
to 2.62; ﬁgure 2).26 28 30 31 There was substantial hetero-
geneity in this meta-analysis (I2=76%), with Sosa’s study
reporting signiﬁcantly increased fracture risk,28 while
the others did not.
However, we judged a study by Sosa et al28 to be at
high risk of bias because the control group consisted of
relatives and neighbours of patients, the type of ICS was
not reported and there were no statistical adjustments
for confounders. In this data set, Johannes et al26 was the
only study reporting fractures according to dose, but this
did not demonstrate any consistent trend towards ele-
vated risk at higher doses.
Lumbar spine BMD
Three RCTs and three observational studies reported on
comparative change at the lumbar spine in chil-
dren.15 19 20 22 23 25 (ﬁgure 3) ICS use was not associated
with signiﬁcant reductions in BMD as compared to con-
trols in RCTs (mean difference −0.0018 g/cm2; 95% CI
−0.0051 to 0.0015 g/cm2; I2=46%) or observational studies
(mean difference −0.0075 g/cm2; 95% CI −0.044 to
0.028 g/cm2; I2=42%). There was no clear signal of dose
responsiveness in one observational study that separated
Figure 2 Fracture risk, ICS use
versus non-use. ICS, inhaled
corticosteroids.
Figure 3 BMD in lumbar spine children, ICS use versus non-use. BMD, bone mineral density; ICS, inhaled corticosteroids.
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participants into different dose levels,25 whereas one RCT
suggested that longer term users of budesonide with
greater cumulative doses had lower BMD compared to
those who received lower cumulative doses.20
Three RCTs and four observational studies reported
on comparative change in BMD at the lumbar spine in
adults (ﬁgure 4).16–18 24 28 30 31 ICS use was not asso-
ciated with signiﬁcant reductions in BMD as compared
to controls in RCTs (mean difference −0.0019 g/cm2;
95% CI −0.0075 to 0.0038 g/cm2; I2=0%) or observa-
tional studies (mean difference −0.0055 g/cm2; 95% CI
−0.047 to 0.058 g/cm2; I2=45%).
Femur/hip BMD for adults
There were three RCTs and four observational studies
reporting comparative change in BMD at the femur or
hip in adults (ﬁgure 4).16–18 24 28 30 31 ICS use was not
associated with signiﬁcant reductions in BMD as
compared to controls in RCTs (mean difference
0.0020 g/cm2; 95% CI −0.0030 to 0.0070 g/cm2; I2=0%)
or observational studies (mean difference 0.0070 g/cm2;
95% CI −0.045 to 0.059 g/cm2; I2=73%).
There was sparse data comparing different ICS mole-
cules head to head. Ferguson et al14 measured lumbar
spine BMD and reported a non-signiﬁcant ﬁnding
between children randomised to ﬂuticasone propionate
100 μg twice daily as compared to budesonide, mean dif-
ference 0.0075 g/cm2 (95% CI −0.033 to 0.048 g/cm2).
Maspero conducted a ﬁve arm trial that included mometa-
sone and ﬂuticasone propionate in adults. There were no
signiﬁcant differences in lumbar spine and femur BMD
between the two compounds at the end of the trial.18
Figure 4 BMD in adults, ICS use versus non-use. BMD, bone mineral density; ICS, inhaled corticosteroids; RCT, randomised
controlled trial.
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We did not proceed to constructing a funnel plot for
detection of publication bias because we had less than
10 studies in the meta-analysis of each outcome, and
there was substantial heterogeneity.
DISCUSSION
We focused our systematic review of RCTs and observa-
tional studies on skeletal adverse effects of ICS in patients
with asthma. We did not ﬁnd convincing evidence of
increased fracture risk with ICS use in adults or children.
Equally, there was no consistent evidence of any signiﬁ-
cant detrimental relationship between ICS use and BMD
at the lumbar spine (in adults and children) or femur (in
adults). There was insufﬁcient data for us to detect any
dose–response relationship, or to judge any potential dif-
ferences between the available ICS molecules.
Our ﬁndings should be contrasted with those of other
recent published reviews. There have been at least four
systematic reviews evaluating fractures or BMD in ICS
users, with two earlier reviews demonstrating a signiﬁ-
cant reduction in BMD but no deﬁnite impact on frac-
tures.5 33 The most recent meta-analyses have identiﬁed
a small but statistically signiﬁcant dose-related increase
in risk of fracture associated with ICS use in patients
with COPD.6 7 Our ﬁndings differ from these other
reviews as we have speciﬁcally focused on ICS use in
patients with asthma. Here, we used very rigid selection
criteria in an attempt to exclude patients with COPD
from our meta-analysis.
The deleterious effects of ICS on BMD seen in previous
meta-analyses could be explained in part by the higher
prevalence of smoking in patients with COPD as previous
studies have shown that smoking has a harmful effect on
BMD, and increasing fracture risk.8 In addition, as a
group, patients with asthma are likely to be younger and
to have fewer comorbidities than those with COPD which
may impact on BMD and fracture risk. Recent research
indicates that multimorbidity (including cachexia and
low-grade systemic inﬂammation) is often seen in patients
with COPD,9 and it is conceivable that these factors may
have a further negative impact on bone formation that
accentuate the risks of ICS in COPD.
ICS therapy may have a positive impact on bone
density through reduction of chronic inﬂammation and
avoidance of need for acute short courses of oral corti-
costeroids during exacerbations. In addition, ICS may
allow better control of asthma in patients such that they
become more active, thereby slowing or preventing
steroid-induced osteoporosis through the beneﬁcial
effects of physical activity on BMD. Bone mass can also
be inﬂuenced by a wide range of other factors (such as
nutrition, genetic make-up, endocrine status and
amount of physical exercise),1 and ICS may therefore
not be the most important inﬂuence on bone density in
patients with asthma.
There are a number of limitations to our systematic
review. Our search was limited to English language
articles. Although, studies have attempted to assess skel-
etal adverse effects in many different ways, we have
limited our review to clinically meaningful outcomes
such as BMD in g/cm2 at lumbar spine and femur, and
fractures. We did not have sufﬁcient data from the
primary studies for us to conduct meaningful analyses
on different combinations of drug compounds, inhaler
devices and dosage regimens. Some of the included
studies were published more than a decade ago, and
advances in asthma care may have made their ﬁndings
less applicable to current-day patients. We recognise that
there is potential for risk of bias (stemming from sub-
stantial loss to follow-up for BMD measurements) within
this data set. Hence, we are unable to interpret the
effects of ICS in very long-term use of ICS over a decade
or more.
Our systematic review demonstrates that there is no
consistent evidence of serious skeletal harm from use of
ICS. Although there are intrinsic limitations to the evi-
dence, we believe that our systematic review provides
some reassurance to patients and prescribers of ICS.
Our ﬁndings enables ICS users to judge the beneﬁts
and harms of their medication in a more accurate
manner and helps to address concerns and uncertainty
surrounding the exact risk of skeletal adverse effects.
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